[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646692":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":37,"centralContacts":41,"locations":49,"responsibleParty":65,"collaborators":67,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":11,"enrollmentInfo":83,"targetDuration":11,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":11,"overallStatus":93,"whyStopped":11,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Opioid + Metamizole","EXPERIMENTAL",null,[13],"Drug: Metamizole",{"label":15,"type":10,"description":11,"interventionNames":16},"Opioid + Ibuprofen",[17],"Drug: Ibuprofen",{"label":19,"type":20,"description":11,"interventionNames":21},"Opioid + Placebo","PLACEBO_COMPARATOR",[22],"Other: Placebo",[24,29,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","Metamizole","Metamizole 4 g\u002Fd as: 2 capsules of 500 mg Metamizole each (1000 mg) taken 4 x daily orally.",[9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Ibuprofen","Ibuprofen 1.2 g\u002Fd as: 2 capsules of 150 mg Ibuprofen each (300 mg) taken 4 x daily orally",[15],{"type":6,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"Placebo","Placebo 0 g\u002Fd as: 2 capsules containing inactive substance (mannitol) taken 4 x daily orally.",[19],[38],{"name":39,"affiliation":5,"role":40},"Christopher Boehlke, Prof. Dr.","PRINCIPAL_INVESTIGATOR",[42,46],{"name":39,"role":43,"phone":44,"phoneExt":11,"email":45},"CONTACT","+41 61 265 25 25,","christopher.boehlke@unibas.ch",{"name":47,"role":43,"phone":11,"phoneExt":11,"email":48},"Ursina Wernli, PhD","ursina.wernli@usb.ch",[50],{"facility":51,"status":11,"city":52,"state":11,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"University Hospital Basel","Basel","4031","Switzerland","CH",{"type":57,"coordinates":58},"Point",[59,60],7.57327,47.55839,{"lat":60,"lon":59},[63],{"name":39,"role":43,"phone":64,"phoneExt":11,"email":45},"+41 61 265 25 25",{"type":66,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[68,71],{"name":69,"class":70},"Swiss GO Trial Group","NETWORK",{"name":72,"class":6},"Swiss National Science Foundation","100646692","phase-3-efficacy-of-non-opioid-drugs-in-addition-to-opioid-therapy-for-cancer-pain-management-100646692",false,"NCT07682558","Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management","Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management: a Double-blind, Randomized, Three Arm, Placebo Controlled Trial Assessing the Key Non-opioids Dipyrone (Metamizole) and Ibuprofen","NoDoubt","Inclusion Criteria:\n\n* Inpatient setting (discharge possible, if patient returns for End of Study Visit)\n* Diagnosis of metastatic or locally advanced cancer\n* Cancer pain as defined by IASP (International Association for the Study of Pain)\n* Cancer pain therapy with opioids indicated for pain management or start thereof at baseline (drug, dose, and route at treating physician's discretion)\n* Average daily pain intensity ≥ 3 on NRS (Numeric Rating Scale)\n* Ability to swallow oral medication\n* Informed Consent as documented by signature\n\nExclusion Criteria:\n\n* History of allergy or allergy-like symptoms (bronchospasm, urticaria or severe cutaneous adverse reactions (SCARs)) or hypersensitivity to dipyrone (or other pyrazolones or pyrazolidines) or ibuprofen (or other Non-steroidal anti-inflammatory drug incl. acetylsalicylic acid)\n* Moderate to severe renal insufficiency (creatinine-eGFR (estimated Glomerular Filtration Rate) \\\u003C45 ml\u002Fmin)\n* Severe heart failure (New York Heart Association class III-IV)\n* Severe hepatic impairment (liver cirrhosis with ascites) or hepatic porphyria\n* History of agranulocytosis induced by dipyrone (or other pyrazolones or pyrazolidines)\n* Active gastric and\u002For duodenal ulcers or bleeding\n* History of recurrent gastric and\u002For duodenal ulcers or gastrointestinal bleeding (≥2 distinct episodes of proven ulceration or bleeding) or increased tendency to bleeding\n* Third trimester of pregnancy\n* Breastfeeding\n* G6PD deficiency\n* Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)\n* Intrathecal or epidural opioids or local or regional anesthetic therapy\n* Additional second opioid for co-analgesic effects or other reasons (e.g., methadone, buprenorphine)\n* Initiation of therapy with transdermal therapeutic system (TTS) opioid \\\u003C48 hours before start of IMP\n* Use of non-opioids with long half-life (i.e., acemetacin, celecoxib, etodolac, etoricoxib, ketorolac, naproxen, piroxicam, tenoxicam)\n* Pain unrelated to cancer (e.g. chronic non-cancer pain \\[CNCP\\], postoperative, particularly following coronary artery or cardiopulmonary bypass surgery)\n* Inability to follow study procedures or adhere to protocol (e.g., due to language problems, psychological disorders, dementia)\n* Inability to abstain from other non-opioids (apart from IMP (Investigational Medicinal Product)) during study participation\n* Participation in any interventional study targeted at pain management\n* Participant is a family member or employee of the investigator","ALL","18 Years",{"count":84,"type":85},318,"ESTIMATED","INTERVENTIONAL",[88],"PHASE3","The investigators investigate the efficacy of non-opioid analgesics compared to placebo together with opioid therapy for cancer pain management.",[91,92],"Cancer Pain","Cancer Palliative Care","NOT_YET_RECRUITING","2026-08-18",{"date":96,"type":97},"2026-08-19","ACTUAL",{"date":99,"type":85},"2026-10",{"date":101,"type":85},"2029-11",{"name":5,"class":6},1]